SCHEMBL7950900

SCHEMBL7950900

O=S1(=O)N=C(NC2CCCC2)Nc2cc(F)ccc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.38
ABCC8 Q09428 1/20 0.38
KCNJ11 Q14654 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.36
HTR5A P47898 1/20 0.35
CXCR2 P25025 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA12 O43570 1/20 0.34
CA4 P22748 1/20 0.34
CA7 P43166 1/20 0.34
CA9 Q16790 1/20 0.34
JAK2 O60674 4/20 0.34
MLLT1 Q03111 1/20 0.33
NR1I2 O75469 1/20 0.33
CYP2C9 P11712 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HPGD P15428 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4262374 0.90 ABCC8 (0.45) MAPTABCC8KCNJ11L3MBTL1HTR5A
SCHEMBL6554548 0.87 ABCC8 (0.48) MAPTABCC8KCNJ11L3MBTL1HTR5A
SCHEMBL24050255 0.86 ABCC8 (0.45) MAPTABCC8KCNJ11HTR5ACXCR2
SCHEMBL7952015 0.84 CA12 (0.44) ABCC8KCNJ11L3MBTL1CXCR2CA1
SCHEMBL6553120 0.83 ABCC8 (0.48) MAPTABCC8KCNJ11HTR5ACXCR2
SCHEMBL718852 0.83 MEN1 (0.39) MAPTCA1CA2KDM4E
SCHEMBL718174 0.80 ABCC8 (0.44) MAPTABCC8KCNJ11CXCR2CA1
SCHEMBL718689 0.80 MAPT (0.56) MAPTABCC8KCNJ11HTR5ACA1
SCHEMBL24050507 0.80 ABCC8 (0.53) MAPTABCC8KCNJ11CXCR2CA1
SCHEMBL717798 0.79 ABCC8 (0.52) MAPTABCC8KCNJ11CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1081633-C 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof NOVO NORDISK AS (DK) 2002-03-27 CN claimed
US-6242443-B1 1,2,4-benzothiadiazine derivatives, their preparation and use NOVO NORDISK AIS (DK) 2001-06-05 US claimed
CN-1222910-A 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof NOVO NORDISK AS (DK) 1999-07-14 CN claimed
US-12209140-B2 Therapeutics for the treatment of glaucoma MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2025-01-28 US disclosed
US-20230101009-A1 THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2023-03-30 US disclosed
US-11505572-B2 Therapeutics for the treatment of glaucoma MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2022-11-22 US disclosed
US-10981951-B2 Therapeutics for the treatment of glaucoma MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2021-04-20 US disclosed
US-20210040148-A1 THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2021-02-11 US disclosed
US-20170002040-A1 NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH 2017-01-05 US disclosed
CN-1081633-C 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof NOVO NORDISK AS (DK) 2002-03-27 CN disclosed
US-6242443-B1 1,2,4-benzothiadiazine derivatives, their preparation and use NOVO NORDISK AIS (DK) 2001-06-05 US disclosed
CN-1222910-A 1,2, 4-benzothiadiazine derivatives, method for preparing same and use thereof NOVO NORDISK AS (DK) 1999-07-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230101009-A1 THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA KCNJ1, KCNJ2, KCNJ11 MAPT 3115/4885ABCC8 62/4885KCNJ11 3/4885
US-20210040148-A1 THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA KCNJ1, KCNJ2, KCNJ11 MAPT 3115/4885ABCC8 62/4885KCNJ11 3/4885
US-12209140-B2 Therapeutics for the treatment of glaucoma KCNJ1, KCNJ2, KCNJ11 MAPT 3115/4885ABCC8 62/4885KCNJ11 3/4885
US-20170002040-A1 NOVEL THERAPEUTICS FOR THE TREATMENT OF GLAUCOMA KCNJ1, KCNK4, KCNK2 MAPT 3160/4885ABCC8 67/4885KCNJ11 4/4885
US-11505572-B2 Therapeutics for the treatment of glaucoma KCNJ1, KCNJ2, KCNJ11 MAPT 3115/4885ABCC8 62/4885KCNJ11 3/4885
US-10981951-B2 Therapeutics for the treatment of glaucoma KCNJ1, KCNJ2, KCNJ11 MAPT 3115/4885ABCC8 62/4885KCNJ11 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.